Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations

Hagit Shani, Rinat Bernstein-Molho, Yael Laitman, Iris Netzer, Eitan Friedman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Purpose: The co-occurrence or double heterozygosity of pathogenic/likely pathogenic sequence variants (P/LPSVs) in major cancer susceptibility genes has rarely been reported. Such co-occurrence raises the issues of accurate genetic counseling, preferred recommended surveillance scheme, and the use of preimplantation genetic diagnosis (PGD). Methods: A clinical report of an Ashkenazi Jewish (AJ) family with co occurrence of two PSVs in BRCA1 and TP53 and a literature search. Results: In an AJ family with a substantial history of cancer limited to the maternal side, two siblings co-harbored TP53 (c.733C>A; p.G245S) and the predominant 5266dup BRCA1 mutation, originating from the mother and the father, respectively. PGD is ongoing. Four families were thus far reported as double heterozygotes for both BRCA1/BRCA2 and TP53. Based on the limited available data, it seems that the phenotype in double PSV heterozygotes is not more severe than in single PSV carrier in either gene. Conclusions: This family highlights the need to genotype both parents, especially in populations with founder mutations, when a BRCA1 mutation is detected in an offspring, regardless of family history. The combination of mutations in these two genes presents a challenge for PGD since both genes are located on chromosome 17.

Original languageEnglish
Pages (from-to)259-263
Number of pages5
JournalBreast Cancer Research and Treatment
Volume186
Issue number1
DOIs
StatePublished - Feb 2021

Keywords

  • Ashkenazi Jews
  • BRCA1
  • Double heterozygosity
  • Founder mutations
  • Pathogenic sequence variants
  • TP53

Fingerprint

Dive into the research topics of 'Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations'. Together they form a unique fingerprint.

Cite this